Company Analysis
Sign in

Neurocrine Biosciences, Inc. (NBIX)

Nasdaq: NBIX · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 1996
Full chart Alerts Compare
Grade7.4
◀ Past 8.4● Present 7.8▶ Future 5.8
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

128 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Neurocrine Biosciences, Inc.’s names, not what it holds today.

Patents granted
128
128 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 3 in 2024 and 4 in 2023
Applications published
188
8 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals19
Organic fine chemistry11
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Neurocrine Biosciences, Inc. its own name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in CA)
128 granted
90 published
Neurocrine Biosciences, Inc. its own name
named as the applicant on its applications, in US
0 granted
98 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,486,250Muscarinic receptor 4 antagonists and methods of useOrganic fine chemistryNeurocrine Biosciences, Inc.
Sep 23, 202512,421,193GPR52 modulators and methods of useOrganic fine chemistryNeurocrine Biosciences, Inc.
Aug 12, 202512,383,536CRF receptor antagonists and methods of useOrganic fine chemistryNeurocrine Biosciences, Inc.
Oct 29, 202412,128,033Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-aminePharmaceuticalsNeurocrine Biosciences, Inc.
Oct 1, 202412,102,637Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosisPharmaceuticalsNeurocrine Biosciences, Inc.
Sep 10, 202412,083,227Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosisPharmaceuticalsNeurocrine Biosciences, Inc.
Aug 22, 202311,730,739Treatment of congenital adrenal hyperplasiaPharmaceuticalsNeurocrine Biosciences, Inc.
Aug 8, 202311,718,618Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitorsPharmaceuticalsNeurocrine Biosciences, Inc.
Aug 1, 202311,713,324Gonadotropin-releasing hormone receptor antagonists and methods relating theretoOrganic fine chemistryNeurocrine Biosciences, Inc.
May 23, 202311,654,142Methods for the administration of certain VMAT2 inhibitorsPharmaceuticalsNeurocrine Biosciences, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0333413SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORSPharmaceuticalsNeurocrine Biosciences, Inc.
Oct 30, 20252025/0333404DEUTERATED COMPOUNDSOrganic fine chemistryNeurocrine Biosciences, Inc.
Sep 11, 20252025/0282792GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETOOrganic fine chemistryNeurocrine Biosciences, Inc.
Jul 3, 20252025/0213486Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or AdenomyosisPharmaceuticalsNeurocrine Biosciences, Inc.
Mar 20, 20252025/0092022MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USEPharmaceuticalsNeurocrine Biosciences, Inc.
Feb 27, 20252025/0064990METHODS OF SCREENING FOR VMAT2 INHIBITORSPharmaceuticalsNeurocrine Biosciences, Inc.
Jan 2, 20252025/0000862PHARMACEUTICAL FORMULATIONS FOR TREATING ENDOMETRIOSIS, UTERINE FIBROIDS, POLYCYSTIC OVARY SYNDROME OR ADENOMYOSISPharmaceuticalsNeurocrine Biosciences, Inc.
Jan 2, 20252025/0000805VALBENAZINE COMPOSITIONSPharmaceuticalsNeurocrine Biosciences, Inc.
Dec 12, 20242024/0408086USE OF LUVADAXISTAT FOR THE TREATMENT OF COGNITIVE IMPAIRMENTPharmaceuticalsNeurocrine Biosciences, Inc.
Oct 17, 20242024/0342160VALBENAZINE FOR USE IN THE TREATMENT OF DYSKINESIA DUE TO CEREBRAL PALSYPharmaceuticalsNeurocrine Biosciences, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 16 · Organic fine chemistry 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NBIX · research, not advice